PT - JOURNAL ARTICLE AU - Capelle, Christophe M. AU - Cire, Séverine AU - Domingues, Olivia AU - Ernens, Isabelle AU - Hedin, Fanny AU - Fischer, Aurélie AU - Snoeck, Chantal AU - Ammerlaan, Wim AU - Konstantinou, Maria AU - Grzyb, Kamil AU - Skupin, Alex AU - Carty, Cara L. AU - Hilger, Christiane AU - Gilson, Georges AU - Celebic, Aljosa AU - Sol, Antonio Del AU - Kaplan, Ian M. AU - Betsou, Fay AU - Abdelrahman, Tamir AU - Cosma, Antonio AU - Vaillant, Michel AU - Fagherazzi, Guy AU - Ollert, Markus AU - Hefeng, Feng Q. TI - Deep immune profiling reveals early-stage and highly coordinated immune responses in mild COVID-19 patients AID - 10.1101/2021.08.31.21262713 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.31.21262713 4099 - http://medrxiv.org/content/early/2021/09/02/2021.08.31.21262713.short 4100 - http://medrxiv.org/content/early/2021/09/02/2021.08.31.21262713.full AB - While immunopathology has been widely studied in severe COVID-19 patients, immunoprotective factors in non-hospitalized patients have remained largely elusive. We systematically analyzed 484 peripheral immune cell signatures, various serological parameters and TCR repertoire in a longitudinal cohort of 63 mild and 15 hospitalized patients versus 14 asymptomatic and 26 control individuals. Within three days following PCR diagnosis, we observed coordinated responses of CD4 and CD8 T cells, various antigen presenting cells and antibody-secreting cells in mild, but not hospitalized COVID-19 patients. This early-stage SARS-CoV-2-specific response was predominantly characterized by substantially expanded clonotypes of CD4 and less of CD8 T cells. The early-stage responses of T cells and dendritic cells were highly predictive for later seroconversion and protective antibody levels after three weeks in mild non-hospitalized, but not in hospitalized patients. Our systemic analysis provides the first full picture and early-stage trajectory of highly coordinated immune responses in mild COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04380987Clinical Protocols https://bmjopen.bmj.com/content/bmjopen/10/11/e041834.full.pdf Funding StatementWe first would like to acknowledge the active involvement of all the anonymous participants in the Predi-COVID cohort. We are also thankful for the excellent support of the recruitment team of the Predi-COVID cohort from CIEC of LIH. The Predi-COVID study is supported by the Luxembourg National Research Fund (FNR) (Predi-COVID, 14716273) and the Andre Losch Fondation. We also highly appreciate the expert support of the IBBL processing and biorepository teams. F.Q.H. was partially supported by FNR CORE programme grant (CORE/14/BM/8231540/GeDES), FNR AFR-RIKEN bilateral programme (TregBAR, 11228353, F.Q.H. and M.O.) and PRIDE programme grants (PRIDE/11012546/NEXTIMMUNE and PRIDE/10907093/CRITICS). C.H. was partially supported by the FNR fast-track call COVID-19/2020-1/14703957/COV-Immun.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Luxembourg National Research Ethics Committee has given approval to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN.A.